G2GBio Signs Deal With UBT to Evaluate Long-Acting Injectable Drugs

• G2GBio signed material transfer and platform evaluation agreements with China's United Bio-Technology (Hengqin) on Oct. 19, 2026.
• The InnoLAMP platform will be applied to a UBT-provided drug candidate to assess its potential for development as a long-acting injectable.
• The contract includes milestone payments, with an upfront payment equivalent to at least 10% of the previous fiscal year's revenue.
• The agreement runs until research ends or 12 months from signing, whichever comes first, with extensions possible by mutual written agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. G2GBio Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261019900400), on October 19, 2026, and is solely responsible for the information contained therein.